• CTLA-4 (CD152)is a negative checkpoint regulatorwhich has been largely investigated in cancer immunotherapy. Recentfindings indicate that CTLA-4 correlates with immune and clinicalcharacteristics of glioma.213,221. Here, CTLA4 is linked to central nervous system cancer.